Browse by author
Lookup NU author(s): Dr Dipayan Mitra
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022 Elsevier LtdHomogeneous and common objective disease assessments and standardised response criteria are important for better international clinical trials for CNS germ cell tumours. Currently, European protocols differ from those of North America (the USA and Canada) in terms of criteria to assess radiological disease response. An international working group of the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group was therefore established to review existing literature and current practices, identify major challenges regarding imaging assessment, and develop consensus recommendations for imaging response assessment for patients with CNS germ cell tumours. New clinical imaging standards were defined for the most common sites of CNS germ cell tumour and for the definition of locoregional extension. These new standards will allow the evaluation of response to therapy in patients with CNS germ cell tumours to be more consistent, and facilitate direct comparison of treatment outcomes across international studies.
Author(s): Morana G, Shaw D, MacDonald SM, Alapetite C, Ajithkumar T, Bhatia A, Brisse H, Jaimes C, Czech T, Dhall G, Fangusaro J, Faure-Conter C, Fouladi M, Hargrave D, Harreld JH, Mitra D, Nicholson JC, Souweidane M, Timmermann B, Calaminus G, Bartels U, Bison B, Murray MJ
Publication type: Review
Publication status: Published
Journal: The Lancet Oncology
Year: 2022
Volume: 23
Issue: 5
Pages: e218-e228
Print publication date: 01/05/2022
Online publication date: 27/04/2022
Acceptance date: 02/04/2018
ISSN (print): 1470-2045
ISSN (electronic): 1474-5488
Publisher: Elsevier Ltd
URL: https://doi.org/10.1016/S1470-2045(22)00063-8
DOI: 10.1016/S1470-2045(22)00063-8
PubMed id: 35489353
